Xenon expands 2025 inducement equity share pool
Xenon Pharmaceuticals Inc. amended and restated its 2025 Inducement Equity Incentive Plan to expand the share pool used for new-hire equity awards.
Rhea-AI Filing Summary
Xenon Pharmaceuticals Inc. amended and restated its 2025 Inducement Equity Incentive Plan to expand the share pool used for new-hire equity awards. The maximum number of common shares reserved under the plan increased from 900,000 to 1,175,000 shares, subject to adjustment under the plan’s terms.
These shares may be granted as nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, or performance awards, and are intended as inducements for individuals being hired or rehired as employees of Xenon or its subsidiaries. In line with Nasdaq Listing Rule 5635(c)(4), shareholder approval was not obtained for this inducement-only plan.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Previous inducement plan share reserve: 900,000 shares
New inducement plan share reserve: 1,175,000 shares
Approval standard: Nasdaq Listing Rule 5635(c)(4)
+1 more
4 metrics
Previous inducement plan share reserve
900,000 shares
Maximum common shares reserved under 2025 Inducement Plan before amendment
New inducement plan share reserve
1,175,000 shares
Maximum common shares reserved under amended and restated 2025 Inducement Plan
Approval standard
Nasdaq Listing Rule 5635(c)(4)
Basis for not seeking shareholder approval of inducement-only equity plan
Plan amendment date
April 7, 2026
Date Xenon Pharmaceuticals amended and restated its 2025 Inducement Plan
Key Terms
2025 Inducement Equity Incentive Plan, nonstatutory stock options, restricted stock units, Nasdaq Listing Rule 5635(c)(4), +1 more
5 terms
2025 Inducement Equity Incentive Plan financial
"amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan"
nonstatutory stock options financial
"to be used exclusively for grants of nonstatutory stock options, stock appreciation rights"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
restricted stock units financial
"stock appreciation rights, restricted stock units, restricted stock, and performance awards"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Nasdaq Listing Rule 5635(c)(4) regulatory
"In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek approval"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
performance awards financial
"restricted stock units, restricted stock, and performance awards as an inducement"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Xenon Pharmaceuticals Inc. (XENE) change in its 2025 Inducement Equity Incentive Plan?
Xenon Pharmaceuticals increased the share pool under its 2025 Inducement Equity Incentive Plan. The maximum common shares reserved rose from 900,000 to 1,175,000, allowing more equity awards to be granted to new or rehired employees as hiring incentives.
What types of awards can Xenon Pharmaceuticals (XENE) grant under the amended 2025 Inducement Plan?
Under the amended plan, Xenon can grant nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, and performance awards. These awards serve as inducements that are considered material to attracting or rehiring employees for Xenon and its subsidiaries.
Who is eligible to receive awards under Xenon Pharmaceuticals’ 2025 Inducement Plan?
Eligible recipients are individuals being hired, or rehired after a bona fide break in employment, as employees of Xenon Pharmaceuticals or its subsidiaries. The equity awards are intended to be material inducements for accepting employment offers with the company.
When did Xenon Pharmaceuticals (XENE) approve the amendments to the 2025 Inducement Plan?
Xenon Pharmaceuticals approved the amended and restated 2025 Inducement Equity Incentive Plan on April 7, 2026. This action expanded the reserved share pool for inducement-based equity awards to support future employee hiring and rehiring activities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
